ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 6 of 25
УЖМБС 2022, 7(4): 41–47
Clinical Medicine

Biomarker Levels Dynamics of Endothelial Function in Patients with Treatment Resistant Hypertension under the Influence of Treatment

Kulbachuk O. S., Dmytrieva S. М., Sid’ Ye. V., Soloviov O. V., Piskun A. V.

The purpose of the study was to determine the biomarker levels dynamics of endothelial function in patients with treatment resistant hypertension under the influence of treatment. Materials and methods. A comprehensive outpatient examination was conducted in 117 patients with a preliminary diagnosis of treatment resistant hypertension. 71 patients with hypertension of the stage II and 35 practically healthy individuals were examined. The quantitative content of endothelin-1 was determined by enzyme immunoassay using a set of reagents Endothelin-1 ELISA kit (Biomedica, Austria). The method for determining stable final metabolites of nitric oxide in the blood is based on the reduction of nitrates to nitrites with the determination of the latter by reaction with the Gris reagent. Results and discussion. The level of endothelin-1 between the groups of patients was significantly higher among patients with treatment resistant hypertension than among patients with hypertension of the stage II – 1.64 [1.16; 2.18] fmol/l versus 0.98 [0.73; 1.02] fmol/l, respectively, (p<0.05). The NO2 index had the lowest value in the group of patients with treatment resistant hypertension 6.00 [5.10; 7.30] mmol/l and was significantly lower by 20.0% compared to the group of patients with hypertension of the stage II – 7.50 [6.80; 9.40] mmol/L. The NO3 level among patients with treatment resistant hypertension was 13.50 [11.20; 14.80] mmol/l, which was significantly lower by 11.8% and 18.2% compared to the group of patients with hypertension of the stage II and the group of practically healthy individuals, respectively (p<0.05). In the first group, blood pressure levels <140/90 mmHg were reached by 29 (56.9%) people, which significantly exceeded the percentage in the second group – 15 (30.6%) patients (p<0.05). Treatment of patients with treatment resistant hypertension should include optimizing dosages and prescribing rational combinations of antihypertensive drugs in order to enhance synergistic effects. Among the measures to overcome low adherence to treatment of hypertension, the following should be recommended: assessment and selection of patients with low compliance (according to the Morisky-Green scale); optimization of pharmacotherapy by prescribing drugs with fixed combinations; control of drug intake. The Morisky-Green scale test should be applied at the beginning of treatment of patients with hypertension, since it allows the doctor to understand how supportive the patient is to treatment and will correctly perform the appointment. After all, only accurate and correct execution of prescriptions can bring the maximum positive effect of therapy and prevent the development of complications. The fixed combination of amlodipine-indapamide-perindopril has one important advantage, which is to increase adherence to treatment due to the principle of "one day – one pill". Conclusion. Among patients with hypertension, the development of endothelial dysfunction is noted, which increases with treatment resistant hypertension. The combination of amlodipine-indapamide-perindopril is effective in reducing blood pressure and correcting endothelial dysfunction. The use of a fixed combination of amlodipine-indapamide-perindopril in the form of a single pill by patients is accompanied by a large percentage of those who have reached blood pressure levels <140/90 mmHg

Keywords: endothelial dysfunction, treatment resistant hypertension

Full text: PDF (Ukr) 255K

  1. Mensah GA, Roth GA, Fuster V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. J Am Coll Cardiol. 2019;74(20): 2529-2532. PMID: 31727292. doi: 10.1016/j.jacc.2019.10.009
  2. Gheorghe A, Griffiths U, Murphy A, Legido-Quigley H, Lamptey P, Perel P. The economic burden of cardiovascular disease and hypertension in low-and middle-income countries: a systematic review. BMC public health. 2018 Aug 6;18(1):975. PMID: 30081871. PMCID: PMC6090747.
  3. doi: 10.1186/s12889-018-5806-x
  4. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982-3021. PMID: 33309175. PMCID: PMC7755038. doi: 10.1016/j.jacc.2020.11.010
  5. Biletskyi SV, Boyko VV, Petrynych OA, Kazantseva TV. Endotelialna dysfunktsiya ta arterialna gipertenziya [Endothelial dysfunction and arterial hypertension (literature review)]. Klin Eksp Patolog. 2017;1:160-163. [Ukrainian]
  6. Brandes RP. Endothelial dysfunction and hypertension. Hypertension. 2014;64(5):924-928. PMID: 25156167. doi: 10.1161/HYPERTENSIONAHA.114.03575
  7. Tseluyko VI. Realii lecheniya arterialnoy gipertenzii v Ukraine: rezultaty kogortnogo issledovaniya SISTEMA-2 [Realities of arterial hypertension treatment in Ukraine: results of the cohort study SYSTEM-2]. Ukr Kardiolog Zh. 2018;1:13-20. [Russian]
  8. Ramzy DI. Definition of hypertension and pressure goals during treatment (ESC-ESH Guidelines 2018). E-Journal of Cardiology Practice . 2019.;17. Available from:
  9. Ábrahám G, Dézsi CA. The antihypertensive efficacy of the triple fixed combination of perindopril, indapamide, and amlodipine: the results of the PETRA study. Adv Ther. 2017 Jul;34(7):1753-1763. PMID: 28646394. doi: 10.1007/s12325-017-0572-1
  10. Páll D, Szántó I, Szabó Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig. 2014 Oct;34(10):701-8. PMID: 25212574. doi: 10.1007/s40261-014-0223-0
  11. MOZ Ukrainy. Nakaz № 384 vid 24.05.2012 r. Arterialna hipertenziya. Onovlena ta adaptovana klinichna nastanova, zasnovana na dokazakh [Arterial hypertension. Updated and adapted clinical setting, based on evidence]. K; 2012. 129 s. [Ukrainian]
  12. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018 Sep 1;39(33):3021-3104. PMID: 30165516. doi: 10.1093/eurheartj/ehy339
  13. Katerenchuk IP, Mokhnachov OV. Komplayens yak peredumova efektyvnosti terapiyi komorbidnoho perebihu hipertonichnoi khvoroby [Compliance as a rethinking of the effectiveness of therapy for comorbid overshoot of hypertensive disease]. Visnyk problem biolohiyi i medytsyny. 2019;2(2):120-123. [Ukrainian]
  14. Mordi I, Mordi N, Delles C, Tzemos N. Endothelial dysfunction in human essential hypertension. J Hypertens. 2016 Aug;34(8):1464-72. PMID: 27203578. doi: 10.1097/HJH.0000000000000965
  15. Virdis A, Taddei S. Endothelial dysfunction in resistance arteries of hypertensive humans: old and new conspirators. J Cardiovasc Pharmacol. 2016 Jun;67(6):451-7. PMID: 26808712. doi: 10.1097/FJC.0000000000000362
  16. Szymański FM, Lip GY, Filipiak KJ. Management of atrial fibrillation in specific patient populations. Kardiol Pol. 2016;74(1):1-8. PMID: 26596895. doi: 10.5603/KP.a2015.0223
  17. Estrada D, Sierra C, Soriano RM, Jordán AI, Plaza N, Fernández C. Grade of knowledge of hypertension in hypertensive patients. Enfermería Clínica (English Edition). 2020;30(2):99-107. doi: 10.1016/j.enfcle.2018.11.003